Search Result

Pathways Recommended:	Metabolic Enzyme/Protease

Results for "

3CL pro protease

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HCV Protease (12) HIV Protease (12) Apoptosis (5) Cathepsin (2) Cytochrome P450 (2) Endogenous Metabolite (2) HCV (12) HIV (12) HSV (2) Isotope-Labeled Compounds (1) MMP (3) P-glycoprotein (2) SARS-CoV (35)
By Research Areas:	Cancer (11) Infection (34) Inflammation/Immunology (4)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: Virus Protease HCV Protease HIV Protease Protease Activated Receptor (PAR) Ser/Thr Protease ClpP Enteropeptidase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108137

Z-LVG-CHN2 2 Publications Verification	Cathepsin HSV SARS-CoV	Infection Inflammation/Immunology
Z-LVG-CHN2 is a cell-permeable and irreversible inhibitor of cysteine proteinase. Z-LVG-CHN2 is a tripeptide derivative and mimics part of the human cysteine proteinase-binding center. Z-LVG-CHN2 displays an inhibition on HSV whereas no significant effect on poliovirus replication. Z-LVG-CHN2 effectively blocks SARS-COV-2 replication (EC₅₀=190 nM) via inhibition of SARS-COV-2 3CL pro protease .

HY-108137A

Z-L(D-Val)G-CHN2	Cathepsin HSV SARS-CoV	Infection
Z-L(D-Val)G-CHN2 is the isoform of Z-LVG-CHN2 (HY-108137). Z-LVG-CHN2 is a cell-permeable and irreversible inhibitor of cysteine proteinase. Z-LVG-CHN2 is a tripeptide derivative and mimics part of the human cysteine proteinase-binding center. Z-LVG-CHN2 displays an inhibition on HSV whereas no significant effect on poliovirus replication. Z-LVG-CHN2 effectively blocks SARS-COV-2 replication (EC₅₀=190 nM) via inhibition of SARS-COV-2 3CL pro protease .

HY-144062

INSCoV-614(1B)	SARS-CoV	Infection
INSCoV-614(1B) is a potent inhibitor of M ^pro (3CL ^pro). Proteases (PL ^pro and 3CL ^pro) are involved with transcription and replication of the virus. INSCoV-614(1B) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .

HY-144061

INSCoV-601I(1)	SARS-CoV	Infection
INSCoV-601I(1) is a potent inhibitor of M ^pro (3CL ^pro). Proteases (PL ^pro and 3CL ^pro) are involved with transcription and replication of the virus. INSCoV-601I(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .

HY-144063

INSCoV-600K(1)	SARS-CoV	Infection
INSCoV-600K(1) is a potent inhibitor of M ^pro (3CL ^pro). Proteases (PL ^pro and 3CL ^pro) are involved with transcription and replication of the virus. INSCoV-600K(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .

HY-139683

Antiviral agent 5

SARS-CoV Infection

Antiviral agent 5 is an intermediate used in antiviral agents targeting 3C and 3CL proteases including SARS-CoV-2 M ^pro.

Antiviral agent 5	SARS-CoV	Infection
Antiviral agent 5 is an intermediate used in antiviral agents targeting 3C and 3CL proteases including SARS-CoV-2 M ^pro.

HY-17007

Saquinavir 5+ Cited Publications Ro 31-8959	HIV HIV Protease SARS-CoV	Infection Cancer
Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy. Saquinavir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 1.36 μM.

HY-144833

SARS-CoV-2 3CLpro-IN-1	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a potent inhibitor of *SARS-CoV-2 3CL* ^pro*. 3CL* ^pro (main coronaviruses cysteine-protease) has been identified as a promising target for the development of antiviral agents. SARS-CoV-2 3CLpro-IN-1 has the potential for the research of infection diseases .

HY-90001

Ritonavir 20+ Cited Publications ABT 538; RTV	HIV Protease HIV SARS-CoV Apoptosis	Infection Cancer
Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 1.61 μM.

HY-137048

PF-00835231 1 Publications Verification	SARS-CoV	Infection
PF-00835231 is a CoV-2 *cysteine 3C-like protease* (3CL ^pro) inhibitor, with IC₅₀*s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CL* ^pro, respectively. PF-00835231 is developed for the research of anti-SARS-CoV-2/COVID-19 sup>[2].

HY-17430

Amprenavir 5+ Cited Publications VX-478	HIV HIV Protease SARS-CoV	Infection Cancer
Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 1.09 μM.

HY-17634

Glecaprevir 5 Publications Verification ABT-493	HCV HCV Protease SARS-CoV	Infection
Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC₅₀ values ranging from 3.5 to 11.3 nM. Glecaprevir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 4.09 μM .

HY-152005

SARS-CoV-2 3CLpro-IN-6	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor of SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro-IN-6 has potent inhibitory activity for SARS-CoV-2 3CL ^pro with an IC₅₀ value of 4.9 μM. SARS-CoV-2 3CLpro-IN-6 can be used for the research of coronavirus disease 2019 (COVID-19) .

HY-90001R

Ritonavir (Standard) ABT 538 (Standard); RTV (Standard)	HIV Protease HIV SARS-CoV Apoptosis	Infection Cancer
Ritonavir (Standard) is the analytical standard of Ritonavir. This product is intended for research and analytical applications. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 1.61 μM.

HY-14434

Asunaprevir 30+ Cited Publications BMS-650032	HCV HCV Protease SARS-CoV	Infection
Asunaprevir (BMS-650032) is a potent and orally bioavailable hepatitis C virus (HCV) NS3 protease inhibitor, with IC₅₀ of 0.2 nM-3.5 nM . Asunaprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-10300

Narlaprevir 4 Publications Verification SCH 900518	HCV HCV Protease SARS-CoV	Infection
Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a K_i value of 6 nM and an EC₉₀ value of 40 nM . Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease . Narlaprevir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 2.3 μM .

HY-151535

SARS-CoV-2 3CLpro-IN-5	SARS-CoV	Infection Inflammation/Immunology
SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor of *3C-like protease* (3CL ^pro)*. SARS-CoV-2 3CLpro-IN-5 has inhibitory activity for 3CL* ^pro with an IC₅₀ value of 3.8 nM. SARS-CoV-2 3CLpro-IN-5 has 9.0% oral bioavailability (BA). SARS-CoV-2 3CLpro-IN-5 can be used for the research of coronavirus disease 2019 (COVID-19) .

HY-138687

Nirmatrelvir Maximum Cited Publications 44 Publications Verification PF-07321332	SARS-CoV	Infection Inflammation/Immunology
Nirmatrelvir (PF-07321332) is a potent and orally active *SARS-CoV 3C-like protease* (3CL ^PRO)** inhibitor. Nirmatrelvir (PF-07321332) targets to the SARS-CoV-2 virus and can be used for COVID-19 research .

HY-15148

Tipranavir 5+ Cited Publications PNU-140690	HIV Protease HIV SARS-CoV	Infection
Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC₅₀s of 66-410 nM . Tipranavir inhibits SARS-CoV-2 3CL ^pro activity .

HY-10237

Boceprevir 25+ Cited Publications EBP 520; SCH 503034	HCV Protease HCV SARS-CoV	Infection
Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a K_i of 14 nM in both enzyme assay and an EC₉₀ of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-17367

Atazanavir 10+ Cited Publications BMS-232632	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite	Infection Cancer
Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 3.49 μM .

HY-17367A

Atazanavir sulfate 10+ Cited Publications BMS-232632 sulfate	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite	Infection Cancer
Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir sulfate is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 3.49 μM .

HY-B0689

Indinavir MK-639 free base; L-735524 free base	HIV HIV Protease Apoptosis MMP SARS-CoV	Inflammation/Immunology Cancer
Indinavir (MK-639 free base) is an orally active and selective HIV-1 protease inhibitor with a K_i of 0.54 nM for PR. Indinavir exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir is also a *SARS-CoV 3CL* ^pro** inhibitor .

HY-10235

Telaprevir 40+ Cited Publications VX-950	HCV Protease HCV SARS-CoV	Infection
Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (K_i) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-14588

Lopinavir 10+ Cited Publications ABT-378	HIV HIV Protease SARS-CoV	Infection Cancer
Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 14.2 μM .

HY-B0689A

Indinavir sulfate 5+ Cited Publications MK-639; L735524	HIV HIV Protease SARS-CoV Apoptosis MMP	Infection Cancer
Indinavir sulfate (MK-639) is an orally active and selective HIV-1 protease inhibitor with a K_i of 0.54 nM for PR. Indinavir sulfate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate is also a *SARS-CoV 3CL* ^pro** inhibitor .

HY-B0689B

Indinavir sulfate ethanolate MK-639 ethanolate; L735524 ethanolate	Apoptosis MMP HIV HIV Protease SARS-CoV	Infection Cancer
Indinavir sulfate ethanolate (MK-639 ethanolate) is an orally active and selective HIV-1 protease inhibitor with a K_i of 0.54 nM for PR. Indinavir sulfate ethanolate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate ethanolate is also a *SARS-CoV 3CL* ^pro** inhibitor .

HY-14588R

Lopinavir (Standard) ABT-378 (Standard)	HIV HIV Protease SARS-CoV	Infection Cancer
Lopinavir (Standard) is the analytical standard of Lopinavir. This product is intended for research and analytical applications. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 14.2 μM .

HY-15298

Grazoprevir 20+ Cited Publications MK-5172	HCV Protease HCV SARS-CoV	Infection
Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-15298A

Grazoprevir potassium salt 20+ Cited Publications MK-5172 potassium salt	HCV HCV Protease SARS-CoV	Infection
Grazoprevir potassium salt (MK-5172 potassium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir potassium salt inhibits SARS-CoV-2 3CL ^pro activity .

HY-15298C

Grazoprevir sodium salt MK-5172 sodium salt	HCV HCV Protease SARS-CoV	Infection
Grazoprevir sodium salt (MK-5172 sodium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir sodium salt inhibits SARS-CoV-2 3CL ^pro activity .

HY-15298B

Grazoprevir hydrate 20+ Cited Publications MK-5172 hydrate	HCV HCV Protease SARS-CoV	Infection
Grazoprevir hydrate (MK-5172 hydrate) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir hydrate inhibits SARS-CoV-2 3CL ^pro activity .

HY-14588S

(rel)-Lopinavir-d8 (rel)-ABT-378-d₈	Isotope-Labeled Compounds	Others
(rel)-Lopinavir-d₈ ((rel)-ABT-378-d₈)is the deuterium labeledLopinavir(HY-14588) . Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 14.2 μM .

HY-12594

Paritaprevir 10+ Cited Publications ABT-450; Veruprevir	HCV Protease HCV SARS-CoV	Infection
Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC₅₀s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .

HY-12594A

Paritaprevir dihydrate ABT-450 dihydrate; Veruprevir dihydrate	HCV Protease HCV SARS-CoV	Infection
Paritaprevir (ABT-450) dihydrate is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC₅₀s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir dihydrate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.31 μM. Paritaprevir dihydrate is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir dihydrate can be enhanced by Ritonavir (a CYP450 inhibitor) .

HY-10238

Danoprevir 15+ Cited Publications ITMN-191; R7227; RO5190591; RG7227	HCV Protease HCV SARS-CoV	Infection
Danoprevir (ITMN-191) is an orally active NS3/4A protease inhibitor for hepatitis C virus (HCV) with an IC₅₀ of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC₅₀ higher than 10 μM). Danoprevir (ITMN-191) inhibits HCV genotypes 1a, 1b, 4, 5, and 6 (IC₅₀s=0.2-0.4 nM) as well as 2b and 3a (IC₅₀s=1.6, 3.5 nM) . Danoprevir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 0.05 μM .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-17367

Atazanavir 10+ Cited Publications BMS-232632	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 3.49 μM .

HY-17367A

Atazanavir sulfate 10+ Cited Publications BMS-232632 sulfate	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir sulfate is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 3.49 μM .


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-14588S

(rel)-Lopinavir-d8
(rel)-Lopinavir-d₈ ((rel)-ABT-378-d₈)is the deuterium labeledLopinavir(HY-14588) . Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 14.2 μM .

(rel)-Lopinavir-d8

(rel)-Lopinavir-d₈ ((rel)-ABT-378-d₈)is the deuterium labeledLopinavir(HY-14588) . Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks